Get the Stockscreener App
1.47
2.08%
0.03
Pre-market:
1.52
0.05
+3.40%
Geron Corp stock is traded at $1.47, with a volume of 16.69M.
It is up +2.08% in the last 24 hours and up +0.00% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.44
Open:
$1.45
24h Volume:
16.69M
Relative Volume:
1.41
Market Cap:
$938.38M
Revenue:
$183.40M
Net Income/Loss:
$-79.99M
P/E Ratio:
-12.23
EPS:
-0.1202
Net Cash Flow:
$-132.69M
1W Performance:
-14.53%
1M Performance:
+0.00%
6M Performance:
+6.52%
1Y Performance:
-11.45%
1-Day Range:
$1.40
$1.51
1-Week Range:
$1.40
$1.75
52-Week Range:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.47 | 919.23M | 183.40M | -79.99M | -132.69M | -0.1202 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Soleus files 5.2% stake in Geron (GERN) via master fund - Stock Titan
Is Geron (GERN) Using Its New ATM Program To Prioritize Flexibility Over Shareholder Dilution? - Yahoo Finance
Geron at TD Cowen: Strategic Growth and Market Expansion - Investing.com
Geron (NASDAQ: GERN) launches $150M ATM sales agreement with TD Cowen - Stock Titan
Geron 10-K: Revenue $183.9M, EPS (0.13) - TradingView
HC Wainwright Issues Optimistic Outlook for Geron Earnings - MarketBeat
Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success - Yahoo Finance
Geron Corporation (NASDAQ:GERN) Q4 2025 Earnings Call Transcript - Insider Monkey
Geron (GERN) Pops on FDA Nod: Is This Small-Cap Biotech Now Underpriced? - AD HOC NEWS
Geron shares drop after Q4 results miss estimates despite Rytelo growth - MSN
Geron Corp (GERN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments - Investing.com Canada
Geron Corp (GERN) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Geron (GERN) Projects Strong Revenue and Manages Expenses for 20 - GuruFocus
Why Geron (GERN) Is Up 8.3% After Narrowing Losses And Boosting 2026 RYTELO Outlook - simplywall.st
Geron Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Geron (NASDAQ:GERN) Releases Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Why Did GERN Stock Tumble 10% Pre-Market Today? - Stocktwits
Geron Q4 Earnings Call Highlights - MarketBeat
Geron Corporation (GERN) Shares Plummet After Missing Q4 2025 Ex - GuruFocus
Earnings call transcript: Geron Q4 2025 results miss forecasts, stock plunges - Investing.com
Geron (GERN) Targets RYTELO Growth with Strategic Actions in 202 - GuruFocus
Geron: Overview of Fourth Quarter Financial Results - Bitget
Geron earnings missed by $0.02, revenue fell short of estimates - Investing.com
GERON ($GERN) Releases Q4 2025 Earnings - Quiver Quantitative
Geron: Q4 Earnings Snapshot - Barchart.com
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - TradingView
RYTELO drives Geron (GERN) 2025 revenue surge and 2026 guidance - Stock Titan
Geron Corporation Reports $184 Million in RYTELO® Revenue for 2025 and Provides 2026 Financial Guidance - Quiver Quantitative
Earnings Summary: Geron Q4 - Benzinga
Cancer drug RYTELO brings in $184M as Geron cuts a third of staff - Stock Titan
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Assessing Geron (GERN) Valuation After Recent Short Term Share Price Momentum - Yahoo Finance
Geron Corp. Stock Hits Day Low of $1.72 Amid Price Pressure - Markets Mojo
Geron (GERN) Set to Announce Q4 Earnings - GuruFocus
Geron (NASDAQ:GERN) Stock Price Up 8.8%Still a Buy? - MarketBeat
Geron Corporation Q4 Financial Announcement Sparks Investor Curiosity - StocksToTrade
Is Geron (GERN) Pricing Look Attractive After Recent Share Price Rebound? - Yahoo Finance
Geron earnings up next: Can RYTELO sustain revenue momentum? By Investing.com - Investing.com South Africa
Geron earnings up next: Can RYTELO sustain revenue momentum? - Investing.com
Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT - Insider Monkey
Geron Plans to Present at Upcoming Investor Conferences - The Manila Times
Geron Corporation Management to Present at Upcoming Investor Conferences in March 2026 - Quiver Quantitative
Does Geron Corporation offer margin of safetyQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - mfd.ru
Geron (NASDAQ:GERN) Trading Down 6%Here's Why - MarketBeat
Geron Corporation (GERN) Stock Analysis: An Insight into the Biotech Player’s 77% Potential Upside - DirectorsTalk Interviews
Top 2 Industrials Stocks That Are Ticking Portfolio Bombs - Benzinga
Gains Report: Will Geron Corporation benefit from geopolitical trendsGold Moves & Fast Moving Trade Plans - baoquankhu1.vn
Geron (GERN) CFO granted 1.66M options and sells shares for taxes - Stock Titan
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MSN Money - MSN
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):